The cost of paediatric and perianal Crohn's disease in Canterbury, New Zealand

New Zealand Medical Journal

Volumn 125, Issue 1349, 2012, Pages

  Lion, Michaela ^a   Gearry, Richard B ^b,c   Day, Andrew S ^b,c   Eglinton, Tim W ^b,c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; AGED; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COLON CROHN DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; MALE; MEDICAL DOCUMENTATION; NEW ZEALAND; PERIANUS CROHN DISEASE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SOCIOECONOMICS; ARTICLE; COST OF ILLNESS; CROHN DISEASE; ECONOMICS; MIDDLE AGED; STATISTICS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84858016517     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17.
2. Farrokhyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001;36(1):2-15.
3. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002;20(10):639-52.
4. Eglinton TW, Gearry RB. Clinical factors predicting disease course in Crohn's disease. Expert Rev Clin Immunol 2010;6(1):41-5.
5. Eglinton T, Reilly M, Chang C, et al. Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. Br J Surg 2010;97(7):1103-9.
6. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131(3):719-28.
7. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32(11):1134-9.
8. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117(1):49-57.
9. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payor perspective. American Journal of Gastroenterology 2000;95(8):1955-60.
10. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. American Journal of Gastroenterology 2000;95(3):677-83.
11. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. American Journal of Gastroenterology 2000;95(2):524-30.
12. Juan J, Estiarte R, Colome E, et al. Burden of illness of Crohn's disease in Spain. Digestive & Liver Disease 2003;35(12):853-61.
13. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53(10):1471-8.
14. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24(8):797-814.
15. Mesterton J, Jonsson L, Almer SH, et al. Resource use and societal costs for Crohn's disease in Sweden. Inflammatory Bowel Diseases 2009;15(12):1882-90.
16. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine 1999;340(18):1398-405.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-9.
19. American Gastroenterological Association Clinical Practice C. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003;125(5):1503-7.
20. Drummond MF. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford; New York: Oxford University Press, 1997.
21. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13(1 Pt 1):1-7.
22. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997;11(5):385-8.
23. Mayberry MK, Probert C, Srivastava E, et al. Perceived discrimination in education and employment by people with Crohn's disease: a case control study of educational achievement and employment. Gut 1992;33(3):312-4.
24. Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut 1994;35(5):665-8.
25. Access Economics. The Economic Cost of Crohn's Disease and Ulcerative Colitis, 2007.
26. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. Journal of Clinical Gastroenterology 1992;14(4):309-17.
27. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. Journal of Clinical Gastroenterology 1992;14(4):318-27.
28. Rosenthal RJ, Bashankaev B, Wexner SD. Laparoscopic management of inflammatory bowel disease. Dig Dis 2009;27(4):560-4.
29. Eshuis EJ, Slors JF, Stokkers PC, et al. Long-term outcomes following laparoscopically assisted versus open ileocolic resection for Crohn's disease. Br J Surg 2010;97(4):563-8.